Swiss Fetal Transplantation Program and Non-enzymatically Isolated Primary Progenitor Cell Types for Regenerative Medicine.

Details

Serval ID
serval:BIB_8895EE5EA322
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Swiss Fetal Transplantation Program and Non-enzymatically Isolated Primary Progenitor Cell Types for Regenerative Medicine.
Journal
Methods in molecular biology
Author(s)
Laurent A., Scaletta C., Hirt-Burri N., Raffoul W., de Buys Roessingh A.S., Applegate L.A.
ISSN
1940-6029 (Electronic)
ISSN-L
1064-3745
Publication state
Published
Issued date
2021
Peer-reviewed
Oui
Volume
2286
Pages
1-24
Language
english
Notes
Publication types: Journal Article
Publication Status: ppublish
Abstract
Primary progenitor cell types adequately isolated from fetal tissue samples present considerable therapeutic potential for a wide range of applications within allogeneic musculoskeletal regenerative medicine. Progenitor cells are inherently differentiated and extremely stable in standard bioprocessing conditions and can be culture-expanded to establish extensive and robust cryopreserved cell banks. Stringent processing conditions and exhaustive traceability are prerequisites for establishing a cell source admissible for further cGMP biobanking and clinical-grade production lot manufacture. Transplantation programs are ideal platforms for the establishment of primary progenitor cell sources to be used for manufacture of cell therapies or cell-based products. Well-defined and regulated procurement and processing of fetal biopsies after voluntary pregnancy interruptions ensure traceability and safety of progeny materials and therapeutic products derived therefrom. We describe herein the workflows and specifications devised under the Swiss Fetal Progenitor Cell Transplantation Program in order to traceably isolate primary progenitor cell types in vitro and to constitute Parental Cell Banks fit for subsequent industrial-scale cGMP processing. When properly devised, derived, and maintained, such cell sources established after a single organ donation can furnish sufficient progeny materials for years of development in translational musculoskeletal regenerative medicine.
Keywords
Biological Specimen Banks/standards, Biomedical Technology/methods, Biomedical Technology/standards, Cell Transplantation/methods, Cell Transplantation/standards, Cells, Cultured, Human Embryonic Stem Cells/cytology, Humans, Practice Guidelines as Topic, Primary Cell Culture/methods, Primary Cell Culture/standards, Regenerative Medicine/methods, Regenerative Medicine/standards, Tissue and Organ Harvesting/methods, Tissue and Organ Harvesting/standards, Tissue and Organ Procurement/standards, Cell therapy, Clinical cell banking, GMP manufacturing, Organ donation, Progenitor cells, Protocols, Transplantation program
Pubmed
Create date
25/05/2020 7:07
Last modification date
30/06/2021 6:34
Usage data